Australian regulators have approved the M.scio implantable sensor, marking the country’s first authorized medical device for continuous intracranial pressure (ICP) monitoring in patients with hydrocephalus. The device, developed by Germany-based Miethke and distributed by B. Braun, has been listed on the Australian Register of Therapeutic Goods as a Class III medical device suitable for hydrocephalus patients of all ages.
Roughly the size of a coin, the sensor is implanted along shunt tubing at the burr hole site and contains a compressible silicone membrane that responds to cerebrospinal fluid pressure changes. These signals are captured by a measuring cell and transmitted wirelessly to a handheld receiver, allowing clinicians to monitor pressure trends in real time. With a sampling rate of 44 hertz, the system generates detailed pressure curves for both short- and long-term monitoring and maintains stable readings with minimal drift for up to four years.
Unlike conventional intracranial pressure monitoring—which typically relies on external drains and requires intensive care observation—the M.scio implant sits fully under the skin without external components. Two versions are available: M.scio Flat, designed for continuous ICP measurement, and M.scio Dome, which additionally enables cerebrospinal fluid drainage and medication administration. Training for clinicians focuses largely on interpreting the data generated by the implant, with B. Braun preparing digital education modules and webinars to support adoption.
Clinical evidence suggests the technology may significantly reduce the need for imaging and invasive monitoring procedures. A study published in Neurosurgery reported a 61% reduction in X-ray scans, 43% fewer MRI scans, 41% fewer CT scans, and a 92% decrease in intracranial pressure monitoring procedures compared with conventional approaches. Researchers also observed fewer shunt revisions and lower radiation exposure. About 70% of patients reported clinical improvement after implantation, with benefits sustained in long-term follow-up.
Hydrocephalus affects roughly one in 800 newborns in Australia, while normal pressure hydrocephalus in older adults is often underdiagnosed and mistaken for other neurodegenerative diseases. The new implant is designed to improve long-term management of shunt function and intracranial pressure control. In Australia, M.scio is currently subsidized under the Medicare Benefits Schedule, with broader reimbursement under review. B. Braun is also exploring cloud-enabled remote monitoring capabilities that would allow clinicians to review pressure data between appointments, potentially supporting more personalized and proactive care.
Click here to read the original news story.